MedTrace Logo

Oral Nutritional Supplementation of Hemodialysis Patients

NCT05333692 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-04-19

No results posted yet for this study

Summary

This study is aimed to demonstrate that increase in serum albumin concentration (week 8 -baseline) after test treatment (Fresubin® Protein Energy DRINK), a standard ONS, is not relevantly smaller than that after control treatment with NEPRO®.

Conditions

  • Hemodialysis Complication

Interventions

DIETARY_SUPPLEMENT

Fresubin® Protein Energy DRINK

1-2 bottles of Fresubin® Protein Energy DRINK per day

DIETARY_SUPPLEMENT

NEPRO® , Abbott

2-4 cans NEPRO® per day

Sponsors & Collaborators

  • Chung Shan Medical University

    collaborator OTHER

  • Fresenius Kabi Taiwan Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-05-06
Completion
2021-05-06

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05333692 on ClinicalTrials.gov